CIMC Safeway released its 3Q26 results: 9M26 revenue was RMB2,464mn (+40.75% YoY), attributable NP was RMB93mn (-6.94% YoY), and recurring attributable NP was RMB84mn (+9.28% YoY). 3Q26 revenue was RMB1,008mn (+87.74% YoY, +12.17% QoQ), attributable NP was RMB47mn (+28.39% YoY, +111.40% QoQ), and recurring attributable NP was RMB43mn (+24.82% YoY, +112.69% QoQ). Revenue and profit recovered notably QoQ in 3Q26. By segment, 9M26 tank container revenue was RMB1,881mn (+43.25% YoY), medical equipment component revenue was RMB220mn (+21.36% YoY), and aftermarket revenue was RMB120mn (+7.13% YoY), with all three segments recording YoY growth. As chemical logistics demand recovers, we believe the company could be well-positioned to benefit as a global tank container leader. Maintain OVERWEIGHT.
9M26 GPM down YoY; cost control optimized
9M26 gross margin was 11.67%, down 2.87pp YoY, as the industry remained in the early stages of a cyclical recovery with intense competition despite recovering tank container demand. 3Q26 gross margin was 11.09%, down 3.63pp YoY but up 0.02pp QoQ. 9M26 expense ratio was 6.52%, down 2.35pp YoY. Specifically, the sales expense ratio was 0.55%, down 0.36pp YoY; the administrative expense ratio was 2.93%, down 1.97pp YoY; the R&D expense ratio was 3.25%, down 0.64pp YoY; and the financial expense ratio was -0.22%, up 0.62pp YoY, due to lower interest income. We attribute overall improvement in expense ratio control to the recovery in revenue scale diluting overall expenses. The 3Q26 expense ratio was 5.89%, down 2.98pp YoY and 0.89pp QoQ. 9M26 net margin was 3.69%, down 2.06pp YoY.
Chemical logistics demand rebounded
As the domestic chemical industry drives recovery in chemical logistics demand, business demand from chemical logistics service providers and tank container lessors has grown, and tank container market demand has recovered. The government has been promoting specialized and containerized transportation of chemicals and the opening of coastal and inland logistics corridors. Tank containers, a multimodal transport vehicle for liquid cargo, may benefit accordingly. Tank containers face high requirements for safety, environmental protection, and global certification. Orders continue to concentrate among leading players. Newly signed orders in 9M26 reached RMB2,343mn (+45.29% YoY). As of end-September, orders on hand stood at RMB1,295mn (+50.82% YoY), down from RMB1,570mn at end-June, owing to fulfillment and delivery of earlier orders.
Earnings forecasts and valuation
Considering that 9M26 gross margin declined 2.87pp YoY and attributable NP declined 6.94% YoY, with the pace of full-year earnings recovery slower than previously expected, owing to intense competition in the tank container industry and price pressure in the early stages of recovery, we lower our 2026/2027/2028 attributable NP forecasts to RMB142/194/310mn (previous: RMB263/383/514mn, down 46/49/40%), corresponding to BVPS of RMB7.68/7.83/8.18. The average 2027E PB of comparable companies on iFind consensus is 1.4x. Considering high YoY growth in newly signed orders and orders on hand in 9M26, and the formation of a second growth curve in the medical equipment components business, we assign the company a 2027E PB of 1.8x, with a target price of RMB14.09 (previous: RMB14.18, based on 1.8x 2026E PB).
Risks: Forex rate fluctuations, a weaker recovery in the chemical logistics sector than we expect, raw-material price volatility.

　　中集环科发布三季报，26Q1-Q3实现营收24.64亿元，同比+40.75%，归母净利0.93亿元，同比-6.94%，扣非归母0.84亿元，同比+9.28%。其中26Q3实现营收10.08亿元，同比/环比+87.74%/+12.17%，归母净利0.47亿元，同比/环比+28.39%/+111.40%，扣非归母0.43亿元，同比/环比+24.82%/+112.69%。公司26Q3收入与利润环比明显修复，分业务看，26Q1-Q3罐式集装箱收入18.81亿元、同比+43.25%，医疗设备部件收入2.20亿元、同比+21.36%，后市场收入1.20亿元、同比+7.13%，三块业务收入均实现同比增长。展望未来，随着化工物流需求回暖，公司作为全球罐箱龙头有望充分受益。维持“增持”评级。
　　26Q1-Q3毛利率同比下降，整体费用管控优化
　　26Q1-Q3公司毛利率11.67%，同比-2.87pp，同比下滑主要系罐箱需求虽回升但处于景气修复初期、行业竞争仍较激烈所致。其中26Q3毛利率11.09%，同比-3.63pp、环比+0.02pp。26Q1-Q3公司期间费用率6.52%，同比-2.35pp。其中销售费用率0.55%，同比-0.36pp；管理费用率2.93%，同比-1.97pp；研发费用率3.25%，同比-0.64pp；财务费用率-0.22%，同比+0.62pp，主要系利息收入减少所致；公司期间费用率整体管控优化，主要系收入规模回升带动总体费用摊薄所致；其中26Q3期间费用率5.89%，同比-2.98pp、环比-0.89pp。26Q1-Q3净利率3.69%，同比-2.06pp。
　　化工物流需求回暖，在手订单同比+50.82%
　　随着国内化工产业带动化工物流需求恢复，化工物流服务商与罐箱租赁商业务需求有所增长，罐箱市场需求回暖。国家长期推动化学品专业化、集装箱化运输，打通沿海与内陆物流通道，罐箱作为液态货物多式联运载体有望受益。罐箱对安全性、环保性与全球认证要求较高，订单持续向头部集中。从订单角度看，26Q1-Q3公司新签订单23.43亿元，同比+45.29%；截至9月底在手订单12.95亿元，同比+50.82%，较6月底的15.70亿元有所回落，主要系前期订单履约交付所致。
　　披露前三季度利润分配预案，分红比例达74%
　　10月24日，公司披露2026年前三季度利润分配预案，拟以总股本6亿股为基数，每10股派发现金红利1.15元（含税），合计派发6,900万元，不送红股、不以资本公积金转增股本，将于董事会批准后2个月内实施。按26Q1-Q3归母净利0.93亿元测算，本次分红比例约74.47%，对应最新收盘价12.70元的股息率约0.91%。此次分红系在年度股东会授权框架下进一步提高分红频次，夯实投资者回报水平。
　　盈利预测与估值
　　考虑到26Q1-Q3毛利率同比下降2.87pp、归母净利同比下降6.94%，全年业绩修复节奏慢于此前预期，主要系罐箱行业竞争激烈，复苏初期价格受到一定压制，我们下调公司2026-2028年归母净利润预测至1.42/1.94/3.10亿元（前值2.63/3.83/5.14亿元，分别下调46%/49%/40%），对应BPS为7.68/7.83/8.18元。可比公司2027年iFind一致预期PB均值为1.4倍，考虑到公司26Q1-Q3新签及在手订单同比高增，医疗设备部件业务第二曲线逐步成型，我们给予公司2027年1.8倍PB估值，目标价14.09元（前值14.18元，对应26年1.8倍PB）。
　　风险提示：汇率波动风险，化工物流行业复苏不及预期，原材料价格波动。

CIMC Safeway released its 1H26 results: 1H26 revenue was RMB1,456mn (+19.96% YoY), attributable NP was RMB45mn (-27.79% YoY), and recurring attributable NP was RMB41mn (-3.32% YoY). 2Q26 revenue was RMB899mn (+49.21% YoY, +61.33% QoQ), and attributable NP was RMB22mn (-44.20% YoY, -1.38% QoQ). The YoY revenue growth in 1H26 was driven by recovering tank container demand, which boosted orders, production, and sales volume, while the YoY decline in attributable NP was owing to lower gross margin amid intensified competition in the tank container market. By segment, 1H26 revenue from tank containers, medical equipment components, and the aftermarket business all recorded YoY growth. 1) 1H26 tank container revenue was RMB1,083mn (+17.20% YoY), driven by recovering tank container market demand, which boosted orders, production, and sales volume; 2) 1H26 medical equipment component revenue was RMB143mn (+19.89% YoY), maintaining rapid growth momentum; 3) 1H26 aftermarket business revenue was RMB80mn (+6.81% YoY), with the service network continuing to be optimized and incremental contributions from full-lifecycle services emerging. We are optimistic that the company, as a global leader in tank container manufacturing, will be among the first to benefit from the industry recovery, while the medical equipment components business continues to boast potential to be a second growth driver. Maintain OVERWEIGHT.
Considering ongoing uncertainty in downstream customer delivery schedules and pressure on profitability in 1H26, we lower our 2026/2027/2028 attributable NP forecasts to RMB263/383/514mn (previous: RMB317/445/525mn, down 17/14/2%), corresponding to BVPS of RMB7.88/8.02/8.37. The average 2026E PB of comparable companies on iFind consensus is 1.6x. Considering the high YoY growth in newly signed orders and orders on hand in 1H26, the formation of a second growth curve in the medical equipment components business, but also intense industry competition and a somewhat delayed pace of overall earnings recovery, we lower our premium and assign the company a 2026E PB of 1.8x, with a target price of RMB14.18 (previous: RMB17.91, on 2.2x 2026E PB).

　　事件描述
　　公司发布2026年半年报，实现营收14.56亿元，同增19.96%；实现归母净利润0.45亿元，同减27.79%；实现扣非归母净利润0.41亿元，同减3.32%。其中，单Q2公司实现营收8.99亿元，同增49.21%；实现归母净利润0.22亿元，同减44.20%；实现扣非归母净利润0.20亿元，同减11.52%。
　　事件点评
　　各产品收入均实现较快增长。分产品来看，标准不锈钢液体罐箱、特种不锈钢液体罐箱、碳钢罐箱、医疗设备部件分别实现营业收入6.50、3.43、0.90、1.43亿元，同比增速分别为14.99%、17.28%、35.69%、19.89%。
　　毛利率、费用率均有所下降。2026H1公司毛利率同减2.39pct至12.07%。费用率方面，2026H1公司期间费用率同减1.92pct至6.95%，其中销售费用率同减0.23pct至0.60%，管理费用率同减1.34pct至3.19%，财务费用率同增0.22pct至-0.17%，研发费用率同减0.57pct至3.33%。
　　化工终端用户需求有所恢复，新签订单同比大幅增长。2026年以来，中国化工终端用户需求有所恢复，推动中国化工物流运营商需求增长，罐箱市场需求回暖。公司持续深耕罐箱制造，积极培育壮大新市场，如做大做强氟化工、电解液、电子级化学品罐箱等，增强竞争优势。2026H1,公司累计新签订单16.65亿元，同增54.25%；截至2026年6月底，公司在手订单15.70亿元，同增86.81%。
　　医疗设备部件业务稳步推进产能建设，打造第二成长曲线。公司将以精密制造为基础，围绕客户需求，稳步推进产能建设，全面提升自动化、数字化水平和稳定交付能力；通过内部孵化、产业合作与外延并购等多元化路径，推动业务向附加值更高的医疗装备核心零部件环节延伸，进一步融入全球优质客户供应链体系。
　　盈利预测与估值
　　预计公司2026-2028年营收分别为30.59、36.79、41.54亿元，同比增速分别为28.02%、20.27%、12.91%；归母净利润分别为1.51、2.25、3.00亿元，同比增速分别为33.83%、49.33%、33.23%。公司2026-2028年业绩对应PE估值分别为52.06、34.86、26.17，维持“增持”评级。
　　风险提示
　　市场景气度不及预期风险；盈利能力恢复不及预期风险；新业务开拓不及预期风险等。

　　中集环科发布半年报，26H1实现营收14.56亿元，同比+19.96%，归母净利0.45亿元，同比-27.79%，扣非归母净利0.41亿元，同比-3.32%。其中26Q2实现营收8.99亿元，同比/环比+49.21%/+61.33%，归母净利0.22亿元，同比/环比-44.20%/-1.38%。公司26H1营收同比增长主要系罐箱需求回升带动订单及产销量增长，归母净利同比下滑或主要系罐箱市场竞争加剧态势下的毛利率下降。分业务来看，公司26H1罐箱、医疗设备部件、后市场业务营业收入均实现同比增长。1）26H1公司罐式集装箱营业收入10.83亿元，同比+17.20%，主要系罐箱市场需求回暖带动订单及产销量增长；2）26H1公司医疗设备部件营业收入1.43亿元，同比+19.89%，保持较快增长态势；3）26H1后市场业务营业收入0.80亿元，同比+6.81%，服务网络持续优化，全生命周期服务增量逐步显现。我们看好公司作为全球罐箱制造龙头率先受益于行业复苏，同时医疗设备部件第二引擎持续培育。维持“增持”评级。
　　26H1毛利率同比下降，期间费用率管控有所优化
　　26H1公司毛利率12.07%，同比-2.39pp；26Q2公司毛利率11.07%，同比/环比-3.30pp/-2.63pp，主要系罐箱需求虽有回升，但处于行业景气修复初期，整体市场竞争仍较为激烈。26H1公司期间费用率6.95%，同比-1.92pp。其中销售费用率0.60%，同比-0.23pp；管理费用率3.19%，同比-1.34pp；研发费用率3.33%，同比-0.57pp；财务费用率-0.17%，同比+0.22pp。公司期间费用率同比下降，主要系收入规模回升带动总体费用摊薄所致。
　　新签及在手订单同比高增，多式联运试点与高端介质打开空间
　　2026年以来中国化工终端用户需求有所恢复，推动中国化工物流运营商需求增长，中国化工产品价格指数由2025年末的3,930回升至26年6月底的4,511，涨幅约14.78%。此外，算力芯片规模化量产推高电子化学品使用需求，公司围绕半导体、新能源、氟化工赛道持续研发适配罐箱，26H1无水氟化氢（AHF）罐箱通过EXSIF及终端客户ORBIA检验。从订单角度看，26H1公司累计新签订单16.65亿元，同比+54.25%；截至6月底在手订单15.70亿元，同比+86.81%，在手订单储备有望为后续业绩提供支撑。
　　医疗设备部件毛利率逆势提升，持续推进品类扩张
　　26H1公司医疗设备部件业务毛利率44.62%，同比+1.64pp。随着医疗设备部件市场需求持续扩容，公司高端医疗影像设备关键零部件的研发与制造能力不断提升，产品范围逐步扩大，客户基础日益丰富。依托压力容器与精密加工领域的技术积累，公司产品能够适配磁共振影像等设备对低温、真空、高压等严苛工况的要求，已实现从供应商到战略合作伙伴的升级。展望未来，公司一方面通过内部挖潜提升产能并推进产能扩张规划，另一方面拓展客户群体与产品种类，医疗设备业务持续向好有望为公司业绩带来积极贡献。
　　盈利预测与估值
　　考虑到下游客户提货节奏仍存不确定性，上半年盈利端承压，我们下调公司2026-2028年归母净利润预测至2.63/3.83/5.14亿元（前值3.17/4.45/5.25亿元，分别下调17%/14%/2%），对应BPS为7.88/8.02/8.37元。可比公司2026年iFind一致预期PB均值为1.6倍，考虑到公司26H1新签及在手订单同比高增，医疗设备部件业务第二曲线逐步成型，但行业竞争较为激烈，整体业绩复苏节奏有所延后，我们下调溢价率，给予公司2026年1.8倍PB估值，目标价14.18元（前值17.91元，对应26年2.2倍PB）。
　　风险提示：汇率波动风险，化工物流行业复苏不及预期，原材料价格波动。